Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2015-01-31
2019-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Specialized Treatment Early in Psychosis (STEP)
NCT00309452
Enhancing the Prospective Prediction of Psychosis
NCT00291200
Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis
NCT01907282
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
NCT05756855
Effects of Neurocognitive and Social Cognitive Remediation in Patients at Ultra-High Risk of Psychosis
NCT02098408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PRIME care
Specialized care in the PRIME clinic
PRIME care
Specialist medication, cognitive behavior therapy, family-focused therapy
Usual care
Usual care in the community
Usual care
Medication and psychotherapy as available form community providers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRIME care
Specialist medication, cognitive behavior therapy, family-focused therapy
Usual care
Medication and psychotherapy as available form community providers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female between 12 and 30 years old.
2. Understand and sign an informed consent (or assent for minors) document in English.
3. Meet diagnostic criteria for prodromal syndrome as per COPS criteria.
Exclusion Criteria
1. Diagnosis of current or lifetime Axis I psychotic disorder, including mood disorder with psychotic symptoms.
2. Impaired intellectual functioning (full-scale IQ\<70). However, those with an IQ in the 65-69 range will not be excluded if they score \>75 on the WRAT Reading.
3. Past or current history of a clinically significant central nervous system disorder that may contribute to prodromal symptoms or confound their assessment.
4. Alcohol or substance dependence in the past 6 months.
12 Years
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Woods, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prevention through Risk Identification Management and Education (PRIME) Clinic
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1411014943
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.